Cardiovascular gene therapy - Human Genome Sciences/Transgene

Drug Profile

Cardiovascular gene therapy - Human Genome Sciences/Transgene

Latest Information Update: 26 Oct 2005

Price : $50

At a glance

  • Originator Human Genome Sciences; Transgene
  • Developer Human Genome Sciences
  • Class Gene therapies
  • Mechanism of Action Connective tissue growth factor inhibitors; Gene transference; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Coronary artery restenosis; Peripheral vascular disorders

Most Recent Events

  • 26 Oct 2005 No development reported - Preclinical for Peripheral vascular disorders in USA (unspecified route)
  • 26 Oct 2005 No development reported - Preclinical for Coronary artery restenosis in USA (unspecified route)
  • 07 Mar 2002 Company deal information has been updated in the overview section of the profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top